Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé
Calgary, Alberta--(Newsfile Corp. - 9 septembre 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l'approbation de la Bourse de croissance TSX (« TSXV ») afin de prolonger la date limite de clôture de son placement privé annoncé précédemment (voir les communiqués de presse des 16 juillet 2026 et 19 août 2026) (le « Placement
2026-09-09 2:37 PM EDT | Marvel Biosciences Corp.
Marvel Biosciences Announces Extension to Closing Date of Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture Exchange ("TSXV") to extend the closing deadline of its previously announced private placement (see July 16, 2026 and August 19, 2026 press releases) (the "Offering"). The deadline by which the Company must file its final closing materials with the TSXV has been extend
2026-09-09 2:32 PM EDT | Marvel Biosciences Corp.
Tevard Biosciences Announces Publication of Preclinical Research Supporting Engineered Suppressor tRNAs for Duchenne Muscular Dystrophy
Boston, Massachusetts--(Newsfile Corp. - September 9, 2026) - Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today highlighted the publication of research conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research in Science Advances. The paper, entitled "Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dy
2026-09-09 2:27 PM EDT | Tevard Biosciences
Maxwell Biosciences Receives FDA Qualified Infectious Disease Product (QIDP) Designation for All-Cause Bacterial and Fungal Pneumonia
Austin, Texas--(Newsfile Corp. - September 8, 2026) - Maxwell Biosciences, a biotechnology company developing a new class of immune-inspired anti-infective therapeutics, today announced that on May 5, 2026, the U.S. Food and Drug Administration (FDA) granted Qualified Infectious Disease Product (QIDP) designation to MXB-22,510-SC, Maxwell's investigational parenteral injectable drug candidate for the treatment of community-acquired pneumonia (CAP) and hospital-acquired (HAP) or ventilator-ass
Biotechnologies, Pharmaceutique
2026-09-08 9:00 AM EDT | Maxwell Biosciences, Inc.
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials. "Keith has substantial experience supporting U.
Biotechnologies, Pharmaceutique
2026-09-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial monitoring visits scheduled for September 2026 and early October 2026 Company receives $3.15 million in VAT refunds into OS Therapies UK, Ltd. subsidiary, with an additional $7.2 million in refundable VAT an
2026-09-08 6:00 AM EDT | OS Therapies
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company'
Biotechnologies, Pharmaceutique, Santé
2026-09-08 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 202
Biotechnologies, Pharmaceutique, Santé
2026-09-04 6:00 PM EDT | Defence Therapeutics Inc.
MustGrow Announces Officer Appointment and Grant of DSUs
Saskatoon, Saskatchewan--(Newsfile Corp. - September 4, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced the appointment of Tyler Reinheimer, CPA, as Director, Finance of the Company and that the board of directors of the Company has authorized and approved the grant of a total of 1,126,954 deferred share units of the Company ("DSUs") to directors (excluding the Company's Chief Excutive Officer an
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-09-04 7:00 AM EDT | MustGrow Biologics Corp.
Nextleaf Solutions Reports Fiscal Q3 2026 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented Canadian cannabis processor, released its financial results for the third quarter ended June 30, 2026. The quarter reflected sequential improvement in net revenue and a significant reduction in excise taxes, supported by a broadened product mix including non-excisable bulk sales and tolling services. Net r
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-09-03 5:01 PM EDT | Nextleaf Solutions Ltd.
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026. Dr Zak
Biotechnologies, Pharmaceutique, Santé
2026-09-03 7:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. All financial figures are expressed in Canadian dollars ($) unless otherwise noted, are prepared in accordance with International Financial Reporting Standards (IFRS), and are unaudited. In the second quarter o
Technologies, Biotechnologies, Santé
2026-09-03 6:00 AM EDT | Restart Life Sciences Corp.
Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th
White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City. H.C.
Biotechnologies, Soins de santé et hôpitaux
2026-09-02 8:30 AM EDT | Envoy Medical, Inc.
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJapan Interim 3-year overall survival data, U.S. FDA Type C Statistical Methods meeting and U.K. MHRA Statistical Methods Scientific Advice Meeting expected in September 2026 RMAT and Rolling Review decisions expected to fol
2026-09-02 7:20 AM EDT | OS Therapies
Biosenta Enters into Memorandum of Understanding with Dynamic Facility Services for TRUE(TM) Pilot Program
Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") announces that it has entered into a Memorandum of Understanding ("MOU") with Dynamic Facility Services Ltd. ("Dynamic"), a British Columbia-based commercial cleaning and facility services company, to conduct a pilot program evaluating the use of Biosenta's TRUE™ disinfectant within Dynamic's commercial cleaning operations. Under the MOU, Dynamic will conduct a pilot pro
Biotechnologies, Produits chimiques, Produits ménagers / de consommation / cosmétiques
2026-09-01 5:13 PM EDT | Biosenta Inc.
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on September 1, 2027. Vested DSUs shall be settled upon the directors' separation from service fr
2026-09-01 5:01 PM EDT | Marvel Biosciences Corp.
TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
Highlights: LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum unit commitment will be negotiated an
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-01 6:45 AM EDT | TempraMed Technologies Ltd.
Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its premium functional food brand, Holy Crap Foods Inc. ("Holy Crap"), has officially launched in the U.S. market through the Amazon USA platform. The initial U.S. rollout features two of the brand's top-performing super seed SKUs alongside a popular variety package. Following a strong ini
Technologies, Biotechnologies, Santé
2026-09-01 6:00 AM EDT | Restart Life Sciences Corp.
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capabi
Biotechnologies, Pharmaceutique, Santé
2026-08-31 3:15 AM EDT | Defence Therapeutics Inc.
Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Off
2026-08-28 5:01 PM EDT | Sharp Therapeutics Corp.